Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalam
Go back to Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalam| (NASDAQ: RYTM) | Delayed: 101.39 +4.60 (4.75%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $96.79 | 52 Week High | $ | |||
| Open | $97.80 | 52 Week Low | $ | |||
| Day High | $102.14 | P/E | N/A | |||
| Day Low | $97.44 | EPS | $ | |||
| Volume | 1,319,798 | |||||
